Cloud-native electronic lab notebook (ELN) powered by ChemDraw for pharmaceutical, biotech, and chemical R&D teams to capture, share, and collaborate on experimental data across chemistry, biology, and formulation workflows.
Signals Notebook is a collaborative, cloud-native electronic lab notebook (ELN) used by over 1 million scientists at 4,000 organizations worldwide. Powered by ChemDraw, the industry-standard chemical drawing tool, it serves chemists, biologists, formulators, and analytical scientists in pharmaceutical, biotechnology, chemical, agrochemical, flavor and fragrance, and oil & gas R&D environments.
The platform enables real-time multidisciplinary collaboration with on-demand experiment sharing within and outside organizations. Scientists can create chemical structures and reactions by pasting SMILES strings or dragging ChemDraw or .mol files directly into the canvas. Materials management and registration capabilities keep track of compounds with continuous barcode inventory support, allowing scientists to track usage without leaving their experiments.
Signals Notebook is available in three editions: Individual (free for single users), Professional (team collaboration), and Enhanced Enterprise Edition (E3) for validation-ready environments. The E3 edition includes multi-tenant environments (sandbox, staging, production) with two release cadences (Agile and Deferred), specifically designed for regulated pharmaceutical and biotech organizations requiring FDA 21 CFR Part 11 compliance.
The platform integrates with Microsoft Office 365, supports AWS cloud deployment, and includes SOC 2 Type 2 attestation for enhanced security. Continuous updates delivered every 4-6 weeks ensure the platform evolves with modern research needs while maintaining compliance for GxP environments.
Pharmaceutical Edition
Signals Notebook Enhanced Enterprise Edition (E3) is validation-ready and designed for pharmaceutical and biotech organizations requiring GxP compliance and FDA 21 CFR Part 11 support. E3 includes multi-tenant architecture with sandbox, staging, and production environments, two release cadences (Agile and Deferred with updates three times per year), and comprehensive validation documentation to reduce IT burden. Private Cloud option also available for organizations requiring greater control.
Core Capabilities
FDA & GxP Compliance
International Standards
Security Certifications
Data Integrity & Validation
Signals Notebook is a cloud-native SaaS platform available on AWS Marketplace with multiple deployment options including Professional cloud edition and Private Cloud edition for organizations requiring greater control. The E3 (Enhanced Enterprise Edition) provides validation-ready environments with multi-tenant architecture comprising sandbox, staging, and production tenants. Web-based access through modern browsers with user experience designed to match consumer applications for rapid adoption. Updates delivered automatically every 4-6 weeks on Agile release cadence, or three times per year (February, June, October) on Deferred release cadence for validated environments.
Platform provides Microsoft Office 365 integration for document management and collaboration. Native ChemDraw integration enables chemical structure drawing and reaction documentation. Materials management system supports barcode scanning for inventory tracking. Advanced encryption, granular access controls, and permissions-based management ensure data security. Real-time collaboration capabilities allow global teams to share experiments and insights with permission-managed access. Platform includes REST API capabilities for integration with other laboratory systems and enterprise applications.
Pricing is undisclosed: no list price or per-user rate is published for any tier. Quotes are custom, from Revvity directly or through AWS Marketplace, based on contract duration and terms. Subscription-based pricing spans three tiers: Individual (free for single users), Professional (team collaboration), and Enhanced Enterprise Edition (E3) for validation-ready environments.
Third-party reviews describe Signals Notebook as high-cost, with price cited as a major barrier to adoption. The platform targets enterprise pharmaceutical, biotechnology, and chemical R&D organisations. Implementation adds cost, with lengthy deployment timelines and extensive training requirements. A free trial and demo are available for evaluation. Pricing is likely based on number of users and selected edition (Professional vs E3). Signals Notebook is used by over 1 million scientists at 4,000 organisations worldwide.
Implementation timelines vary by edition and organizational requirements. According to user reviews, lengthy implementation and extensive training requirements are noted challenges, requiring significant IT resources. However, the platform's modern consumer-app interface design enables rapid user adoption once deployed. Cloud-native SaaS architecture reduces infrastructure setup complexity compared to on-premise systems.
For validated environments, the E3 edition provides comprehensive validation documentation to reduce IT burden and accelerate GxP compliance. Multi-tenant architecture (sandbox, staging, production) supports phased rollout and testing before production deployment. Revvity provides professional services for implementation, validation assistance, and training. The platform's continuous update model (every 4-6 weeks for Agile, three times per year for Deferred) means organizations benefit from rapid enhancement deployment. Reviews indicate that customer-requested features and improvements are developed, though some pharma clients report capacity constraints in addressing all enhancement requests.
PharmaSpotter assessment from published vendor and third-party sources. No user reviews are on file for this product.
Strengths
User reviews highlight key strengths: - Simple, straightforward UI makes creating, sharing, and searching experiments easy with automatic saving - Fast and efficient, enabling seamless cross-referencing between different scientists' experiments - Templates are easy to update and customize for different workflows - Modern consumer-app user experience promotes rapid user adoption - Strong chemical intelligence with native ChemDraw integration for chemistry workflows - Real-time collaboration capabilities enable global teams to work together effectively
Limitations & Open Questions
User reviews identify pain points: - High cost, cited as a significant barrier to adoption - Lengthy implementation timeline requires extensive training and IT resources - Workflow implementation challenging as it relies on Spotfire with added plugins not natively integrated - Big pharma clients report that Revvity lacks capacity to address all enhancement ideas and feature requests despite consistent feedback - One reviewer rated solution 6/10 expressing concerns about vendor's ability to implement customer-requested improvements at scale
Help the community
Share your experience with PerkinElmer Signals Notebook anonymously. Your insights help pharmaceutical professionals make better software decisions.
Contribute Anonymous FeedbackJump to section